Artiva Shares Surge 46% on Positive AlloNK Phase 2a Safety Data

Introduction

Artiva Biotherapeutics Inc (ticker: ARTV) is a clinical-stage biotechnology company headquartered in San Diego, California. Founded in 2019, Artiva focuses on developing off-the-shelf, allogeneic natural killer (NK) cell therapies for patients with autoimmune diseases and cancer. Its lead product candidate, AlloNK®, is a non-genetically modified, cryopreserved NK cell therapy designed to enhance the activity of B-cell targeted monoclonal antibodies (mAbs).

Corporate Structure

Artiva operates with a workforce of 51–200 employees and maintains its executive offices in San Diego. The leadership team includes President and CEO Fred Aslan, MD, and CMO Subhashis Banerjee, MD, supported by a board of directors and scientific advisors with extensive experience in cell therapy development. Artiva’s shares trade on the NASDAQ under the symbol ARTV.

NK cell therapy by National Cancer Institute

Recent Developments and News

• On May 5, 2025, the U.S. Food and Drug Administration cleared Artiva’s Investigational New Drug application for an open-label Phase 2a basket trial (ClinicalTrials.gov Identifier: NCT06991114) evaluating AlloNK in combination with rituximab across refractory rheumatoid arthritis, Sjögren’s disease, idiopathic inflammatory myopathies, and systemic sclerosis.
• In August 2025, Artiva treated the first patient in this Phase 2a study.
• On November 12, 2025, initial safety and translational data from ongoing trials of AlloNK plus anti-CD20 mAbs demonstrated outpatient feasibility, consistent B-cell depletion by Day 13, and no Grade 3+ AlloNK-related adverse events. A webcast to discuss these findings was held on November 12, 2025.
• On November 5, 2025, Artiva reported third-quarter 2025 financial results and business highlights, announcing plans for FDA discussions in the first half of 2026 to align on pivotal trial design for AlloNK in refractory rheumatoid arthritis.
• On October 20, 2025, the company’s team volunteered at the Jacobs & Cushman San Diego Food Bank under Pledge 1%, assembling 24,208 meals for local families.

Financial and Strategic Analysis

As of December 15, 2025, Artiva’s stock price stood at USD 4.8311, reflecting a 46.40% increase on the day, with a trading volume of 2,197,541 shares. The share price movement coincided with the announcement of safety data and upcoming regulatory discussions. Strategically, Artiva holds ex-APAC rights to its NK cell programs and is evaluating AlloNK in multiple investigator- and company-sponsored trials. Partnerships include combinations with rituximab and innate cell engager platforms such as Affimed’s AFM13.

Market Position and Industry Context

The global cell therapy market is expanding, driven by advances in autologous CAR-T therapies and emerging allogeneic approaches. NK cell therapies offer potential advantages in manufacturing scalability, cryopreservation, and outpatient administration. Artiva positions itself in a niche focused on B-cell driven autoimmune diseases—an area characterized by high unmet need, limited treatment options for refractory patients, and reliance on long-term immunosuppression.

tl;dr

• On December 15, 2025, ARTV shares rose 46.40% to USD 4.8311 on volume of 2.2 million.
• Phase 2a trial of AlloNK® plus rituximab enrolled its first patient in August 2025; no Grade 3+ AlloNK-related events reported.
• Initial safety and translational data (November 12, 2025) support outpatient feasibility and consistent B-cell depletion.
• Artiva plans FDA discussions in H1 2026 to finalize pivotal trial design for refractory rheumatoid arthritis.